Integrating MyMedi.ca healthcare provider-guided medical cannabis care into hospitals, specialty clinics, insurers and multidisciplinary healthcare networks in Canada TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”), a commercial-stage international biopharmaceutical company focused on cannabinoid-based medicines, is pleased to announce the MyMedi.ca Integrated Healthcare Program (“Program”), a new program designed to integrate medical cannabis care and patient support into Canadian healthcare institutions and clinical networks. The program extends the MyMedi.ca platform beyond traditional medical cannabis and referral channels and is intended to support hospitals, specialty clinics, multidisciplinary healthcare networks, insurers and other healthcare organizations seeking to incorporate structured...

Telesat’s entry onto the list underscores the company’s robust TSX performance over a three-year period in the lead-up to the launch of Telesat Lightspeed OTTAWA, Ontario, Sept. 09, 2026 (GLOBE NEWSWIRE) — Telesat Corporation (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, is pleased to announce that it has been named to this year’s TSX30. The TMX Group’s flagship annual ranking recognizes the top 30 performing companies on the Toronto Stock Exchange based on dividend-adjusted share price performance over a three-year period ending on June 30, 2026. Telesat’s share price grew 475% over this three-year period, corresponding to approximately $2.97 billion in incremental market capitalization.1 The strong performance occurs as Telesat prepares for the launch of Telesat Lightspeed, its advanced...

ROGERS, Ark., Sept. 09, 2026 (GLOBE NEWSWIRE) — America’s Car-Mart, Inc. (NASDAQ: CRMT) (“we,” “Car-Mart” or the “Company”), today reported financial results for the first quarter ended July 31, 2026. President and CEO Doug Campbell commentary:  Our first quarter results reflect the capital constraints that have defined our results over the last several quarters. With limited capacity to purchase inventory and fund originations, retail units were down 81.9% and revenue was down 57.3%. Inventory ended the quarter at $35.2 million against $112.5 million a year ago. This is a capital structure story, not a demand story. Application volume was limited by the vehicles we had available to sell. Credit performance was also weaker. Net charge-offs were 9.5% of average finance receivables against 6.6% a year ago, and accounts over 30 days...

HAMBURG, Germany and AUSTIN, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) — XCHG Limited (“XCharge” or the “Company”) (Nasdaq: XCH), a global provider in high-power EV charging solutions, today announced that the Company received a written compliance notification (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on September 8, 2026, informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) for continued listing on Nasdaq. As previously announced, on June 24, 2026, the Company was notified by Nasdaq that it was not in compliance with the Minimum Bid Price Requirement, as the closing bid price of the Company’s American Depositary Shares (“ADSs”) was below $1.00...

Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and QTORIN™ trial investigator brings deep understanding of the unmet needs in serious, rare skin diseases including vascular anomalies Dr. Treat to lead medical strategy as Palvella moves QTORIN™ rapamycin toward potential approval and commercialization for microcystic lymphatic malformations and advances its pipeline of first-in-disease therapies WAYNE, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing...

GOM and NPA LNG futures each reached their highest monthly trading volumes to date, with aggregate LNG volume increasing 24% over July. Trading conditions improved even as headline volume fell. Outright trades rose to 15% of all activity, bid-ask spreads narrowed in multiple active contracts, and order book depth increased, reflecting ongoing efforts to create the conditions for broader commercial participation. Total volume declined to 377,949 contracts from July’s record high, but remained above June levels. Six-month trading volume and ADV were more than 10x those of the preceding six-month period, while average daily open interest more than doubled.TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (TSX:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company,...

MELBOURNE, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) — Orion180 Insurance Group Inc. (“Orion180”), a leading provider of flexible, customer-centric homeowners and flood insurance solutions, today announced that it has launched the roadshow for its proposed initial public offering of its Class A common stock. Orion180 has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) to offer 20,000,000 shares of its Class A common stock to the public. In addition, Orion180 intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is expected to be between $15.00 and $17.00 per share. Orion180 has...

New research commissioned by TransUnion highlights organizations’ incident response vulnerabilities CHICAGO, Sept. 09, 2026 (GLOBE NEWSWIRE) — Cyberattacks are becoming more frequent, disruptive and difficult for organizations to remediate quickly. In the past 18 months, 60% of organizations experienced at least one material impact, according to a commissioned study conducted by Forrester Consulting on behalf of TransUnion (NYSE: TRU). The research, based on a survey of 327 director-level and above decision-makers who influence or make decisions on incident response strategy, found 40% said their organization lacks an end-to-end incident response partner, while 37% said they do not have a comprehensive incident response plan in place. The full findings will be discussed in the upcoming webinar, Close the Incident Response Gap: How...

JERSEY, Channel Islands — September 9, 2026 — CoinShares PLC (Nasdaq: CSHR) (“CoinShares” or the “Company”), a leading global asset manager specializing in digital assets, today announced that President and Chief Executive Officer Jean-Marie Mognetti will attend the Oppenheimer Fintech Leaders Conference in New York, taking place September 15, 2026. Mr. Mognetti will host one-on-one meetings with investors throughout the day. The meetings will cover CoinShares’ business, recent developments, and outlook for the industry. Event DetailsEvent Oppenheimer Fintech Leaders ConferenceDate Tuesday, September 15, 2026Format One-on-one investor meetingsLocation Thompson Central Park Hotel, New York, NYAttendee Jean-Marie Mognetti, President & CEO, CoinShares  Investors, analysts and members of...

            Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential of RAD301 and continuation of its clinical development SYDNEY, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced positive data from the Phase 1 imaging trial designed to evaluate the safety, biodistribution and dosimetry of RAD 301 in healthy volunteers and subjects with Pancreatic Ductal Adenocarcinoma (PDAC). RAD301 is a peptide-based molecule bound to Gallium-68 (Ga-68) that targets...